Fibronectin maintains the balance between hemostasis and thrombosis

Cellular and Molecular Life Sciences

Volumn 73, Issue 17, 2016, Pages 3265-3277

  Wang, Yiming ^a,b,c,d   Ni, Heyu ^a,b,c,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d Toronto Platelet Immunobiology Group   (Canada)

Author keywords

Coagulation factors; Collagen; Fibrinogen and fibrin; Fibronectin; Integrins; Platelet

Indexed keywords

FIBRONECTIN; INTEGRIN;

AMINO TERMINAL SEQUENCE; BLOOD CLOTTING; DEEP VEIN THROMBOSIS; HEMOSTASIS; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA SPLICING; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOSIS; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; FIBRONECTINS; HEMOSTASIS; HUMANS; INTEGRINS; RNA SPLICING; THROMBOSIS;

EID: 84964335727     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-016-2225-y     Document Type: Review

References (151)

1. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO (1993) Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119(4):1079–1091
2. Mosher DF (1989) Fibronectin. Academic Press, San Diego
3. Hynes RO (1990) Fibronectins. Springer, New York
4. Ni H, Yuen PS, Papalia JM, Trevithick JE, Sakai T, Fassler R, Hynes RO, Wagner DD (2003) Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci USA 100(5):2415–2419. doi:10.1073/pnas.2628067100
5. Ni H (2006) Unveiling the new face of fibronectin in thrombosis and hemostasis. J Thromb Haemost 4(5):940–942. doi:10.1111/j.1538-7836.2006.01899.x
6. Wang Y, Carrim N, Ni H (2015) Fibronectin orchestrates thrombosis and hemostasis. Oncotarget 6(23):19350–19351
7. Morrison PR, Edsall JT, Miller SG (1948) Preparation and properties of serum and plasma proteins; the separation of purified fibrinogen from fraction I of human plasma. J Am Chem Soc 70(9):3103–3108
8. Stathakis NE, Mosesson MW (1977) Interactions among heparin, cold-insoluble globulin, and fibrinogen in formation of the heparin-precipitable fraction of plasma. J Clin Invest 60(4):855–865. doi:10.1172/JCI108840
9. Stathakis NE, Mosesson MW, Chen AB, Galanakis DK (1978) Cryoprecipitation of fibrin–fibrinogen complexes induced by the cold-insoluble globulin of plasma. Blood 51(6):1211–1222
10. Gahmberg CG, Hakomori SI (1973) Altered growth behavior of malignant cells associated with changes in externally labeled glycoprotein and glycolipid. Proc Natl Acad Sci USA 70(12):3329–3333
11. Hynes RO (1973) Alteration of cell-surface proteins by viral transformation and by proteolysis. Proc Natl Acad Sci USA 70(11):3170–3174
12. Ruoslahti E, Vaheri A, Kuusela P, Linder E (1973) Fibroblast surface antigen: a new serum protein. Biochim Biophys Acta 322(2):352–358
13. Ruoslahti E, Vaheri A (1974) Novel human serum protein from fibroblast plasma membrane. Nature 248(5451):789–791
14. Yamada KM, Weston JA (1974) Isolation of a major cell surface glycoprotein from fibroblasts. Proc Natl Acad Sci USA 71(9):3492–3496
15. Hynes RO, Wyke JA (1975) Alterations in surface proteins in chicken cells transformed by temperature-sensitive mutants of Rous sarcoma virus. Virology 64(2):492–504
16. Stone KR, Smith RE, Joklik WK (1974) Changes in membrane polypeptides that occur when chick embryo fibroblasts and NRK cells are transformed with avian sarcoma viruses. Virology 58(1):86–100
17. Hogg NM (1974) A comparison of membrane proteins of normal and transformed cells by lactoperoxidase labeling. Proc Natl Acad Sci USA 71(2):489–492
18. Ruoslahti E (1988) Fibronectin and its receptors. Annu Rev Biochem 57:375–413. doi:10.1146/annurev.bi.57.070188.002111
19. Keski-Oja J, Mosher DF, Vaheri A (1976) Cross-linking of a major fibroblast surface-associated glycoprotein (fibronectin) catalyzed by blood coagulation factor XIII. Cell 9(1):29–35
20. Kuusela P, Ruoslahti E, Engvall E, Vaheri A (1976) Immunological interspecies cross-reactions of fibroblast surface antigen (fibronectin). Immunochemistry 13(8):639–642
21. Vaheri A, Ruoslahti E, Mosher DF (1978) Fibroblast surface protein: [papers from a conference held by the New York Academy of Sciences, New York, Nov. 30– Dec. 2, 1977]. Ann N Y Acad Sci 312:1–456
22. Schwarzbauer JE, Tamkun JW, Lemischka IR, Hynes RO (1983) Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell 35(2 Pt 1):421–431
23. Kornblihtt AR, Pesce CG, Alonso CR, Cramer P, Srebrow A, Werbajh S, Muro AF (1996) The fibronectin gene as a model for splicing and transcription studies. FASEB J 10(2):248–257
24. Sakai T, Johnson KJ, Murozono M, Sakai K, Magnuson MA, Wieloch T, Cronberg T, Isshiki A, Erickson HP, Fassler R (2001) Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med 7(3):324–330. doi:10.1038/85471
25. Takahashi S, Leiss M, Moser M, Ohashi T, Kitao T, Heckmann D, Pfeifer A, Kessler H, Takagi J, Erickson HP, Fassler R (2007) The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. J Cell Biol 178(1):167–178. doi:10.1083/jcb.200703021
26. Reheman A, Yang H, Zhu G, Jin W, He F, Spring CM, Bai X, Gross PL, Freedman J, Ni H (2009) Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood 113(8):1809–1817. doi:10.1182/blood-2008-04-148361
27. Muro AF, Chauhan AK, Gajovic S, Iaconcig A, Porro F, Stanta G, Baralle FE (2003) Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. J Cell Biol 162(1):149–160. doi:10.1083/jcb.200212079
28. Fukuda T, Yoshida N, Kataoka Y, Manabe R, Mizuno-Horikawa Y, Sato M, Kuriyama K, Yasui N, Sekiguchi K (2002) Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res 62(19):5603–5610
29. Astrof S, Crowley D, Hynes RO (2007) Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectin. Dev Biol 311(1):11–24. doi:10.1016/j.ydbio.2007.07.005
30. Schwarzbauer JE (1991) Fibronectin: from gene to protein. Curr Opin Cell Biol 3(5):786–791
31. Pankov R, Yamada KM (2002) Fibronectin at a glance. J Cell Sci 115(Pt 20):3861–3863
32. White ES, Muro AF (2011) Fibronectin splice variants: understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life 63(7):538–546. doi:10.1002/iub.493
33. Leiss M, Beckmann K, Giros A, Costell M, Fassler R (2008) The role of integrin binding sites in fibronectin matrix assembly in vivo. Curr Opin Cell Biol 20(5):502–507. doi:10.1016/j.ceb.2008.06.001
34. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E (1986) Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 231(4745):1559–1562
35. Ruoslahti E, Pierschbacher MD (1986) Arg-Gly-Asp: a versatile cell recognition signal. Cell 44(4):517–518
36. Pierschbacher MD, Ruoslahti E (1984) Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc Natl Acad Sci USA 81(19):5985–5988
37. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673–687
38. Yang JT, Rayburn H, Hynes RO (1993) Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 119(4):1093–1105
39. Yang JT, Bader BL, Kreidberg JA, Ullman-Cullere M, Trevithick JE, Hynes RO (1999) Overlapping and independent functions of fibronectin receptor integrins in early mesodermal development. Dev Biol 215(2):264–277. doi:10.1006/dbio.1999.9451
40. Geiger B, Bershadsky A, Pankov R, Yamada KM (2001) Transmembrane crosstalk between the extracellular matrix–cytoskeleton crosstalk. Nat Rev Mol Cell Biol 2(11):793–805. doi:10.1038/35099066
41. Pankov R, Cukierman E, Katz BZ, Matsumoto K, Lin DC, Lin S, Hahn C, Yamada KM (2000) Integrin dynamics and matrix assembly: tensin-dependent translocation of alpha(5)beta(1) integrins promotes early fibronectin fibrillogenesis. J Cell Biol 148(5):1075–1090
42. Singh P, Carraher C, Schwarzbauer JE (2010) Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol 26:397–419. doi:10.1146/annurev-cellbio-100109-104020
43. Aota S, Nomizu M, Yamada KM (1994) The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J Biol Chem 269(40):24756–24761
44. Bowditch RD, Hariharan M, Tominna EF, Smith JW, Yamada KM, Getzoff ED, Ginsberg MH (1994) Identification of a novel integrin binding site in fibronectin. Differential utilization by beta 3 integrins. J Biol Chem 269(14):10856–10863
45. Cho J, Mosher DF (2006) Role of fibronectin assembly in platelet thrombus formation. J Thromb Haemost 4(7):1461–1469. doi:10.1111/j.1538-7836.2006.01943.x
46. Ginsberg MH, Forsyth J, Lightsey A, Chediak J, Plow EF (1983) Reduced surface expression and binding of fibronectin by thrombin-stimulated thrombasthenic platelets. J Clin Invest 71(3):619–624
47. Zhai Z, Wu J, Xu X, Ding K, Ni R, Hu W, Sun Z, Ni H (2007) Fibrinogen controls human platelet fibronectin internalization and cell-surface retention. J Thromb Haemost 5(8):1740–1746. doi:10.1111/j.1538-7836.2007.02625.x
48. Ginsberg MH, Painter RG, Forsyth J, Birdwell C, Plow EF (1980) Thrombin increases expression of fibronectin antigen on the platelet surface. Proc Natl Acad Sci USA 77(2):1049–1053
49. Ni H, Papalia JM, Degen JL, Wagner DD (2003) Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood 102(10):3609–3614. doi:10.1182/blood-2003-03-0850
50. Schwarzbauer JE (1991) Identification of the fibronectin sequences required for assembly of a fibrillar matrix. J Cell Biol 113(6):1463–1473
51. McKeown-Longo PJ, Mosher DF (1985) Interaction of the 70,000-mol-wt amino-terminal fragment of fibronectin with the matrix-assembly receptor of fibroblasts. J Cell Biol 100(2):364–374
52. Mosher DF (1975) Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor. J Biol Chem 250(16):6614–6621
53. Wang Y, Reheman A, Spring CM, Kalantari J, Marshall AH, Wolberg AS, Gross PL, Weitz JI, Rand ML, Mosher DF, Freedman J, Ni H (2014) Plasma fibronectin supports hemostasis and regulates thrombosis. J Clin Invest 124(10):4281–4293. doi:10.1172/JCI74630
54. Cho J, Mosher DF (2006) Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi. Blood 107(9):3555–3563. doi:10.1182/blood-2005-10-4168
55. Tomasini-Johansson BR, Kaufman NR, Ensenberger MG, Ozeri V, Hanski E, Mosher DF (2001) A 49-residue peptide from adhesin F1 of Streptococcus pyogenes inhibits fibronectin matrix assembly. J Biol Chem 276(26):23430–23439. doi:10.1074/jbc.M103467200
56. Rostagno AA, Schwarzbauer JE, Gold LI (1999) Comparison of the fibrin-binding activities in the N- and C-termini of fibronectin. Biochem J 338(Pt 2):375–386
57. Corbett SA, Lee L, Wilson CL, Schwarzbauer JE (1997) Covalent cross-linking of fibronectin to fibrin is required for maximal cell adhesion to a fibronectin-fibrin matrix. J Biol Chem 272(40):24999–25005
58. Mosher DF, Schad PE (1979) Cross-linking of fibronectin to collagen by blood coagulation factor XIIIa. J Clin Invest 64(3):781–787. doi:10.1172/JCI109524
59. Moretti FA, Chauhan AK, Iaconcig A, Porro F, Baralle FE, Muro AF (2007) A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived. J Biol Chem 282(38):28057–28062. doi:10.1074/jbc.M611315200
60. Buratti E, Muro AF, Giombi M, Gherbassi D, Iaconcig A, Baralle FE (2004) RNA folding affects the recruitment of SR proteins by mouse and human polypurinic enhancer elements in the fibronectin EDA exon. Mol Cell Biol 24(3):1387–1400
61. Caputi M, Casari G, Guenzi S, Tagliabue R, Sidoli A, Melo CA, Baralle FE (1994) A novel bipartite splicing enhancer modulates the differential processing of the human fibronectin EDA exon. Nucleic Acids Res 22(6):1018–1022
62. Chauhan AK, Iaconcig A, Baralle FE, Muro AF (2004) Alternative splicing of fibronectin: a mouse model demonstrates the identity of in vitro and in vivo systems and the processing autonomy of regulated exons in adult mice. Gene 324:55–63
63. Cramer P, Caceres JF, Cazalla D, Kadener S, Muro AF, Baralle FE, Kornblihtt AR (1999) Coupling of transcription with alternative splicing: RNA pol II promoters modulate SF2/ASF and 9G8 effects on an exonic splicing enhancer. Mol Cell 4(2):251–258
64. Huh GS, Hynes RO (1993) Elements regulating an alternatively spliced exon of the rat fibronectin gene. Mol Cell Biol 13(9):5301–5314
65. Huh GS, Hynes RO (1994) Regulation of alternative pre-mRNA splicing by a novel repeated hexanucleotide element. Genes Dev 8(13):1561–1574
66. Kornblihtt AR, Umezawa K, Vibe-Pedersen K, Baralle FE (1985) Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. EMBO J 4(7):1755–1759
67. White ES, Baralle FE, Muro AF (2008) New insights into form and function of fibronectin splice variants. J Pathol 216(1):1–14. doi:10.1002/path.2388
68. Schwarzbauer JE, Spencer CS, Wilson CL (1989) Selective secretion of alternatively spliced fibronectin variants. J Cell Biol 109(6 Pt 2):3445–3453
69. Liao YF, Gotwals PJ, Koteliansky VE, Sheppard D, Van De Water L (2002) The EIIIA segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J Biol Chem 277(17):14467–14474. doi:10.1074/jbc.M201100200
70. Tan MH, Sun Z, Opitz SL, Schmidt TE, Peters JH, George EL (2004) Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood 104(1):11–18. doi:10.1182/blood-2003-09-3363
71. Chauhan AK, Moretti FA, Iaconcig A, Baralle FE, Muro AF (2005) Impaired motor coordination in mice lacking the EDA exon of the fibronectin gene. Behav Brain Res 161(1):31–38. doi:10.1016/j.bbr.2005.02.020
72. Chauhan AK, Kisucka J, Cozzi MR, Walsh MT, Moretti FA, Battiston M, Mazzucato M, De Marco L, Baralle FE, Wagner DD, Muro AF (2008) Prothrombotic effects of fibronectin isoforms containing the EDA domain. Arterioscler Thromb Vasc Biol 28(2):296–301. doi:10.1161/ATVBAHA.107.149146
73. Guan JL, Hynes RO (1990) Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1. Cell 60(1):53–61
74. Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG (1989) Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol 109(3):1321–1330
75. Zerlauth G, Wolf G (1984) Plasma fibronectin as a marker for cancer and other diseases. Am J Med 77(4):685–689
76. Tomasini-Johansson B, Mosher DF (2009) Plasma fibronectin concentration in inbred mouse strains. Thromb Haemost 102(6):1278–1280. doi:10.1160/TH09-03-0141
77. Wang Y, Gallant RC, Ni H (2016) Extracellular matrix proteins in the regulation of thrombus formation. Curr Opin Hematol 23(3):280–287
78. Mackman N (2008) Triggers, targets and treatments for thrombosis. Nature 451(7181):914–918. doi:10.1038/nature06797
79. Reheman A, Xu X, Reddy EC, Ni H (2014) Targeting activated platelets and fibrinolysis: hitting two birds with one stone. Circ Res 114(7):1070–1073. doi:10.1161/CIRCRESAHA.114.303600
80. Ruggeri ZM (1997) Mechanisms initiating platelet thrombus formation. Thromb Haemost 78(1):611–616
81. Wang Y, Andrews M, Yang Y, Lang S, Jin JW, Cameron-Vendrig A, Zhu G, Reheman A, Ni H (2012) Platelets in thrombosis and hemostasis: old topic with new mechanisms. Cardiovasc Hematol Disord Drug Targets 12(2):126–132
82. Ruggeri ZM (2002) Platelets in atherothrombosis. Nat Med 8(11):1227–1234. doi:10.1038/nm1102-1227
83. Jackson SP (2007) The growing complexity of platelet aggregation. Blood 109(12):5087–5095. doi:10.1182/blood-2006-12-027698
84. Lei X, Reheman A, Hou Y, Zhou H, Wang Y, Marshall AH, Liang C, Dai X, Li BX, Vanhoorelbeke K, Ni H (2014) Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 111(2):279–289. doi:10.1160/TH13-06-0490
85. Nieswandt B, Brakebusch C, Bergmeier W, Schulte V, Bouvard D, Mokhtari-Nejad R, Lindhout T, Heemskerk JW, Zirngibl H, Fassler R (2001) Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 20(9):2120–2130. doi:10.1093/emboj/20.9.2120
86. 2+ signaling elicited by integrin alpha2beta1 and glycoprotein VI under flow. Blood 114(13):2793–2801. doi:10.1182/blood-2008-12-193490
87. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD (2000) Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 106(3):385–392. doi:10.1172/JCI9896
88. Yang H, Reheman A, Chen P, Zhu G, Hynes RO, Freedman J, Wagner DD, Ni H (2006) Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost 4(10):2230–2237. doi:10.1111/j.1538-7836.2006.02116.x
89. Dunne E, Spring CM, Reheman A, Jin W, Berndt MC, Newman DK, Newman PJ, Ni H, Kenny D (2012) Cadherin 6 has a functional role in platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 32(7):1724–1731. doi:10.1161/ATVBAHA.112.250464
90. Reheman A, Tasneem S, Ni H, Hayward CP (2010) Mice with deleted multimerin 1 and alpha-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1. Thromb Res 125(5):e177–e183. doi:10.1016/j.thromres.2010.01.009
91. Gui T, Reheman A, Funkhouser WK, Bellinger DA, Hagaman JR, Stafford DW, Monahan PE, Ni H (2007) In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. Thromb Res 121(2):225–234. doi:10.1016/j.thromres.2007.03.026
92. Wang Y, Vachon E, Zhang J, Cherepanov V, Kruger J, Li J, Saito K, Shannon P, Bottini N, Huynh H, Ni H, Yang H, McKerlie C, Quaggin S, Zhao ZJ, Marsden PA, Mustelin T, Siminovitch KA, Downey GP (2005) Tyrosine phosphatase MEG2 modulates murine development and platelet and lymphocyte activation through secretory vesicle function. J Exp Med 202(11):1587–1597. doi:10.1084/jem.20051108
93. Polanowska-Grabowska R, Simon CG Jr, Gear AR (1999) Platelet adhesion to collagen type I, collagen type IV, von Willebrand factor, fibronectin, laminin and fibrinogen: rapid kinetics under shear. Thromb Haemost 81(1):118–123
94. Wu YP, de Groot PG, Sixma JJ (1997) Shear-stress-induced detachment of blood platelets from various surfaces. Arterioscler Thromb Vasc Biol 17(11):3202–3207
95. Houdijk WP, de Groot PG, Nievelstein PF, Sakariassen KS, Sixma JJ (1986) Subendothelial proteins and platelet adhesion. von Willebrand factor and fibronectin, not thrombospondin, are involved in platelet adhesion to extracellular matrix of human vascular endothelial cells. Arteriosclerosis 6(1):24–33
96. Houdijk WP, Sixma JJ (1985) Fibronectin in artery subendothelium is important for platelet adhesion. Blood 65(3):598–604
97. Houdijk WP, Sakariassen KS, Nievelstein PF, Sixma JJ (1985) Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. J Clin Invest 75(2):531–540. doi:10.1172/JCI111729
98. Bastida E, Escolar G, Ordinas A, Sixma JJ (1987) Fibronectin is required for platelet adhesion and for thrombus formation on subendothelium and collagen surfaces. Blood 70(5):1437–1442
99. Nievelstein PF, D’Alessio PA, Sixma JJ (1988) Fibronectin in platelet adhesion to human collagen types I and III. Use of nonfibrillar and fibrillar collagen in flowing blood studies. Arteriosclerosis 8(2):200–206
100. Wang Y, Ni H (2015) Fibronectin: extra domain brings extra risk? Blood 125(20):3043–3044. doi:10.1182/blood-2015-03-630855
101. Moon DG, Kaplan JE, Mazurkewicz JE (1986) The inhibitory effect of plasma fibronectin on collagen-induced platelet aggregation. Blood 67(2):450–457
102. Santoro SA (1983) Inhibition of platelet aggregation by fibronectin. Biochem Biophys Res Commun 116(1):135–140
103. Dixit VM, Haverstick DM, O’Rourke K, Hennessy SW, Broekelmann TJ, McDonald JA, Grant GA, Santoro SA, Frazier WA (1985) Inhibition of platelet aggregation by a monoclonal antibody against human fibronectin. Proc Natl Acad Sci USA 82(11):3844–3848
104. Thurlow PJ, Kenneally DA, Connellan JM (1990) The role of fibronectin in platelet aggregation. Br J Haematol 75(4):549–556
105. Arneson MA, Hammerschmidt DE, Furcht LT, King RA (1980) A new form of Ehlers–Danlos syndrome. Fibronectin corrects defective platelet function. JAMA 244(2):144–147
106. Kamykowski GW, Mosher DF, Lorand L, Ferry JD (1981) Modification of shear modulus and creep compliance of fibrin clots by fibronectin. Biophys Chem 13(1):25–28
107. Okada M, Blomback B, Chang MD, Horowitz B (1985) Fibronectin and fibrin gel structure. J Biol Chem 260(3):1811–1820
108. Niewiarowska J, Cierniewski CS (1982) Inhibitory effect of fibronectin on the fibrin formation. Thromb Res 27(5):611–618
109. Procyk R, King RG (1990) The elastic modulus of fibrin clots and fibrinogen gels: the effect of fibronectin and dithiothreitol. Biopolymers 29(3):559–565. doi:10.1002/bip.360290311
110. Collet JP, Moen JL, Veklich YI, Gorkun OV, Lord ST, Montalescot G, Weisel JW (2005) The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis. Blood 106(12):3824–3830. doi:10.1182/blood-2005-05-2150
111. Yang H, Lang S, Zhai Z, Li L, Kahr WH, Chen P, Brkic J, Spring CM, Flick MJ, Degen JL, Freedman J, Ni H (2009) Fibrinogen is required for maintenance of platelet intracellular and cell-surface P-selectin expression. Blood 114(2):425–436. doi:10.1182/blood-2008-03-145821
112. Andrews M (2011) Signal-dependent translation of the platelet transcriptome: the effects of alphaIIb beta3 integrin-ligand interaction on platelet protein synthesis. University of Toronto, Toronto
113. Matuskova J, Chauhan AK, Cambien B, Astrof S, Dole VS, Piffath CL, Hynes RO, Wagner DD (2006) Decreased plasma fibronectin leads to delayed thrombus growth in injured arterioles. Arterioscler Thromb Vasc Biol 26(6):1391–1396. doi:10.1161/01.ATV.0000216282.58291.c6
114. Xu X, Wu J, Zhai Z, Zhou R, Wang X, Wang H, Ding K, Sun Z, Ni H (2006) A novel fibrinogen Bbeta chain frameshift mutation in a patient with severe congenital hypofibrinogenaemia. Thromb Haemost 95(6):931–935. doi:10.1160/TH06-01-0020
115. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B (2002) Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 8(10):1175–1181. doi:10.1038/nm782
116. Stalker TJ, Traxler EA, Wu J, Wannemacher KM, Cermignano SL, Voronov R, Diamond SL, Brass LF (2013) Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood 121(10):1875–1885. doi:10.1182/blood-2012-09-457739
117. Hou Y, Carrim N, Wang Y, Gallant RC, Marshall A, Ni H (2015) Platelets in hemostasis and thrombosis: novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis. J Biomed Res 29(6):437–444. doi:10.7555/JBR.29.20150121
118. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Davalos A (2004) Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 35(7):1671–1676. doi:10.1161/01.STR.0000131656.47979.39
119. Kanters SD, Banga JD, Algra A, Frijns RC, Beutler JJ, Fijnheer R (2001) Plasma levels of cellular fibronectin in diabetes. Diabetes Care 24(2):323–327
120. Peters JH, Maunder RJ, Woolf AD, Cochrane CG, Ginsberg MH (1989) Elevated plasma levels of ED1+ (“cellular”) fibronectin in patients with vascular injury. J Lab Clin Med 113(5):586–597
121. Vincent PA, Rebres RA, Lewis EP, Vt Hurst, Saba TM (1993) Release of ED1 fibronectin from matrix of perfused lungs after vascular injury is independent of protein synthesis. Am J Physiol 265(5 Pt 1):L485–L492
122. Prakash P, Kulkarni PP, Lentz SR, Chauhan AK (2015) Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet Toll-like receptor 4. Blood 125(20):3164–3172. doi:10.1182/blood-2014-10-608653
123. Dhanesha N, Ahmad A, Prakash P, Doddapattar P, Lentz SR, Chauhan AK (2015) Genetic ablation of extra domain A of fibronectin in hypercholesterolemic mice improves stroke outcome by reducing thrombo-inflammation. Circulation. doi:10.1161/CIRCULATIONAHA.115.016540
124. Doddapattar P, Gandhi C, Prakash P, Dhanesha N, Grumbach IM, Dailey ME, Lentz SR, Chauhan AK (2015) Fibronectin splicing variants containing extra domain A promote atherosclerosis in mice through toll-like receptor 4. Arterioscler Thromb Vasc Biol 35(11):2391–2400. doi:10.1161/ATVBAHA.115.306474
125. Maurer E, Schaff M, Receveur N, Bourdon C, Mercier L, Nieswandt B, Dubois C, Jandrot-Perrus M, Goetz J, Lanza F, Gachet C, Mangin PH (2015) Fibrillar cellular fibronectin supports efficient platelet function and procoagulant activity. Thromb Haemost 114(6):1175–1188. doi:10.1160/TH14-11-0958
126. Heit JA (2008) The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 28(3):370–372. doi:10.1161/ATVBAHA.108.162545
127. Schulz C, Engelmann B, Massberg S (2013) Crossroads of coagulation and innate immunity: the case of deep vein thrombosis. J Thromb Haemost 11(Suppl 1):233–241. doi:10.1111/jth.12261
128. von Bruhl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, Khandoga A, Tirniceriu A, Coletti R, Kollnberger M, Byrne RA, Laitinen I, Walch A, Brill A, Pfeiler S, Manukyan D, Braun S, Lange P, Riegger J, Ware J, Eckart A, Haidari S, Rudelius M, Schulz C, Echtler K, Brinkmann V, Schwaiger M, Preissner KT, Wagner DD, Mackman N, Engelmann B, Massberg S (2012) Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 209(4):819–835. doi:10.1084/jem.20112322
129. Brill A, Fuchs TA, Savchenko A, Thomas GM, Martinod K, De Meyer SF, Bhandari AA, Wagner DD (2012) Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. doi:10.1111/j.1538-7836.2011.04544.x
130. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD (2010) Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 107(36):15880–15885. doi:10.1073/pnas.1005743107
131. Zardi L, Siri A, Carnemolla B, Santi L, Gardner WD, Hoch SO (1979) Fibronectin: a chromatin-associated protein? Cell 18(3):649–657
132. McMaster GK, Zardi L (1982) DNA-binding domains of human fibronectin. Biochem Biophys Res Commun 107(2):609–617
133. Pecheniuk NM, Elias DJ, Deguchi H, Averell PM, Griffin JH (2008) Elevated plasma fibronectin levels associated with venous thromboembolism. Thromb Haemost 100(2):224–228
134. Farrell DH (2008) New risk factor for venous thromboembolism? Thromb Haemost 100(2):173–174
135. McMillan R, Durette C (2004) Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 104(4):956–960. doi:10.1182/blood-2003-11-3908
136. Severinsen MT, Engebjerg MC, Farkas DK, Jensen AO, Norgaard M, Zhao S, Sorensen HT (2015) Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 152(3):360–362. doi:10.1111/j.1365-2141.2010.08418.x
137. Li C, Piran S, Chen P, Lang S, Zarpellon A, Jin JW, Zhu G, Reheman A, van der Wal DE, Simpson EK, Ni R, Gross PL, Ware J, Ruggeri ZM, Freedman J, Ni H (2011) The maternal immune response to fetal platelet GPIbalpha causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 121(11):4537–4547. doi:10.1172/JCI57850
138. Li J, van der Wal DE, Zhu G, Xu M, Yougbare I, Ma L, Vadasz B, Carrim N, Grozovsky R, Ruan M, Zhu L, Zeng Q, Tao L, Zhai ZM, Peng J, Hou M, Leytin V, Freedman J, Hoffmeister KM, Ni H (2015) Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 6:7737. doi:10.1038/ncomms8737
139. Webster ML, Zhu G, Li Y, Ni H (2008) Fc-independent phagocytosis: implications for intravenous IgG therapy in immune thrombocytopenia. Cardiovasc Hematol Disord Drug Targets 8(4):278–282
140. Zeng Q, Zhu L, Tao L, Bao J, Yang M, Simpson EK, Li C, van der Wal DE, Chen P, Spring CM, Wang M, Zhang L, Ruan C, Hou M, Xia R, Ni H (2011) Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbalpha antibodies. Am J Hematol. doi:10.1002/ajh.22211
141. Li C, Li J, Li Y, Lang S, Yougbare I, Zhu G, Chen P, Ni H (2012) Crosstalk between platelets and the immune system: old systems with new discoveries. Adv Hematol 2012:384685. doi:10.1155/2012/384685
142. Li J, van der Wal DE, Zhu L, Vadasz B, Simpson EK, Li C, Webster ML, Zhu G, Lang S, Chen P, Zeng Q, Ni H (2013) Fc-independent phagocytosis: implications for IVIG and other therapies in immune-mediated thrombocytopenia. Cardiovasc Hematol Disord Drug Targets 13(1):50–58
143. Yougbare I, Lang S, Yang H, Chen P, Zhao X, Tai WS, Zdravic D, Vadasz B, Li C, Piran S, Marshall A, Zhu G, Tiller H, Killie MK, Boyd S, Leong-Poi H, Wen XY, Skogen B, Adamson SL, Freedman J, Ni H (2015) Maternal anti-platelet beta3 integrins impair angiogenesis and cause intracranial hemorrhage. J Clin Invest 125(4):1545–1556. doi:10.1172/JCI77820
144. Yougbare I, Zdravic D, Ni H (2015) Angiogenesis and bleeding disorders in FNAIT. Oncotarget 6(18):15724–15725
145. Ni H, Chen P, Spring CM, Sayeh E, Semple JW, Lazarus AH, Hynes RO, Freedman J (2006) A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 107(7):2976–2983. doi:10.1182/blood-2005-06-2562
146. Palumbo JS, Zogg M, Talmage KE, Degen JL, Weiler H, Isermann BH (2004) Role of fibrinogen- and platelet-mediated hemostasis in mouse embryogenesis and reproduction. J Thromb Haemost 2(8):1368–1379. doi:10.1111/j.1538-7836.2004.00788.x
147. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P (1988) Development of the human coagulation system in the healthy premature infant. Blood 72(5):1651–1657
148. Foster C, Shennan AH (2014) Fetal fibronectin as a biomarker of preterm labor: a review of the literature and advances in its clinical use. Biomark Med 8(4):471–484. doi:10.2217/bmm.14.28
149. Puetz J (2013) Fresh frozen plasma: the most commonly prescribed hemostatic agent. J Thromb Haemost 11(10):1794–1799. doi:10.1111/jth.12351
150. Callum JL, Karkouti K, Lin Y (2009) Cryoprecipitate: the current state of knowledge. Transfus Med Rev 23(3):177–188. doi:10.1016/j.tmrv.2009.03.001
151. Allain JP (1984) Non Factor VIII related constituents in concentrates. Scand J Haematol Suppl 41:173–180